CA2289741A1 - Adjuvant oligonucleotidique - Google Patents

Adjuvant oligonucleotidique Download PDF

Info

Publication number
CA2289741A1
CA2289741A1 CA 2289741 CA2289741A CA2289741A1 CA 2289741 A1 CA2289741 A1 CA 2289741A1 CA 2289741 CA2289741 CA 2289741 CA 2289741 A CA2289741 A CA 2289741A CA 2289741 A1 CA2289741 A1 CA 2289741A1
Authority
CA
Canada
Prior art keywords
oligonucleotide
adjuvant
vaccine
antigen
hbsag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2289741
Other languages
English (en)
Inventor
Michael J. Caulfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2289741A1 publication Critical patent/CA2289741A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne des adjuvants oligonucléotidiques utiles pour provoquer à la fois une réaction à médiation cellulaire (lymphocytes T cytotoxiques) et une réaction immunitaire à un antigène présenté par l'administration d'un vaccin. Des compositions de vaccins renfermant l'adjuvant et des procédés de vaccination employant les adjuvants sont également prévus.
CA 2289741 1997-05-19 1998-05-19 Adjuvant oligonucleotidique Abandoned CA2289741A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4712197P 1997-05-19 1997-05-19
US60/047,121 1997-05-19
PCT/US1998/010459 WO1998052962A1 (fr) 1997-05-19 1998-05-19 Adjuvant oligonucleotidique

Publications (1)

Publication Number Publication Date
CA2289741A1 true CA2289741A1 (fr) 1998-11-26

Family

ID=21947178

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2289741 Abandoned CA2289741A1 (fr) 1997-05-19 1998-05-19 Adjuvant oligonucleotidique

Country Status (5)

Country Link
EP (1) EP0983289A4 (fr)
JP (1) JP2001526688A (fr)
AU (1) AU7589398A (fr)
CA (1) CA2289741A1 (fr)
WO (1) WO1998052962A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO1998055495A2 (fr) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Oligonucleotides immunostimulateurs, compositions correspondantes et leurs procedes d'utilisation
DK1009413T3 (da) 1997-09-05 2007-06-11 Univ California Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma
ES2242376T3 (es) * 1998-02-03 2005-11-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Administracion de particulas inmunogenas mediante particulas de agshb.
US7029680B1 (en) 1998-02-03 2006-04-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Delivery of immunogenic molecules vis HBsAg particles
PT1077722E (pt) * 1998-05-22 2006-12-29 Coley Pharm Group Inc Produtos e composições para utilização na indução da imunidade mucosal
CA2380947C (fr) 1999-08-19 2011-11-01 Dynavax Technologies Corporation Procedes de modulation d'une reponse immunitaire par utilisation de sequences immunostimulantes et compositions utilisees
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
AT409085B (de) * 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
FR2805265B1 (fr) * 2000-02-18 2002-04-12 Aventis Pasteur Oligonucleotides immunostimulants
FR2805264B1 (fr) * 2000-02-18 2002-04-12 Aventis Pasteur Oligonucleotides immunostimulants
US20010046967A1 (en) 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20020098199A1 (en) 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
JP4188687B2 (ja) 2000-12-27 2008-11-26 ダイナバックス テクノロジーズ コーポレイション 免疫変調ポリヌクレオチド及びその使用法
CA2451974C (fr) 2001-06-21 2014-10-14 Karen L. Fearon Composes immunomodulateurs chimeriques et leurs procedes d'utilisation
JP4607452B2 (ja) 2001-08-07 2011-01-05 ダイナバックス テクノロジーズ コーポレイション 免疫調節性組成物、製剤およびその使用方法
IL160157A0 (en) 2001-08-17 2004-07-25 Coley Pharm Group Inc Combination motif immune stimulation oligonucleotides with improved activity
CA2388049A1 (fr) 2002-05-30 2003-11-30 Immunotech S.A. Oligonucleotides immunostimulateurs et utilisations connexes
CA2484941A1 (fr) 2002-07-24 2004-02-05 Intercell Ag Antigenes a phase de lecture alternante a partir de virus
EP2402026A3 (fr) 2002-09-13 2012-04-18 Intercell AG Procédé pour isoler des peptides du virus de l'hépatite C
EP1578954A4 (fr) 2002-12-11 2010-08-11 Coley Pharm Group Inc Acides nucleiques 5'cpg et leurs methodes d'utilisation
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
PT1992635E (pt) 2002-12-23 2012-03-20 Dynavax Tech Corp Oligonucleótidos de sequência imunoestimuladora e métodos de utilização dos mesmos
ATE485056T1 (de) 2003-03-24 2010-11-15 Intercell Ag Verbesserte impfstoffe
US9573979B2 (en) 2004-09-24 2017-02-21 Susanne Modrow Modified VP1-capsid protein of parvovirus B19
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
JP2013521002A (ja) 2010-03-05 2013-06-10 プレジデント アンド フェロウズ オブ ハーバード カレッジ 誘導樹状細胞組成物及びその使用
US9556439B2 (en) 2012-02-09 2017-01-31 Bavarian Nordic A/S Agonists and antagonists of toll-like receptor (TLR) 13

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0468520A3 (en) * 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
ATE509102T1 (de) * 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide

Also Published As

Publication number Publication date
JP2001526688A (ja) 2001-12-18
WO1998052962A1 (fr) 1998-11-26
AU7589398A (en) 1998-12-11
EP0983289A1 (fr) 2000-03-08
EP0983289A4 (fr) 2001-04-25

Similar Documents

Publication Publication Date Title
CA2289741A1 (fr) Adjuvant oligonucleotidique
AU753688B2 (en) Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
KR100900837B1 (ko) 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
CA2412026A1 (fr) Molecules hybrides arn/adn immunostimulatrices
CN112972670B (zh) 免疫刺激组合物及其用途
WO1998040100A9 (fr) UTILISATION D'ACIDES NUCLEIQUES CONTENANT UN DINUCLEOTIDE CpG NON METHYLE EN TANT QU'ADJUVANT
US20240245767A1 (en) Application of artificially synthesized cpg single-stranded deoxyoligonucleotide in vaccines
US12569553B2 (en) Shingles vaccines comprising a TLR9 agonist
US6887464B1 (en) Advanced antigen presentation platform
Wang et al. Adjuvant synergy in the response to hepatitis B vaccines
JP2003520568A (ja) 高度な抗原提示プラットフォーム
JP2025501574A (ja) Ｃｐｇアジュバント帯状疱疹ワクチンの免疫原性
Klinman et al. CpG DNA augments the immunogenicity of plasmid DNA vaccines
US20040191214A1 (en) Nucleoside vaccine adjuvants
KR100359753B1 (ko) 면역조절능력 및 안전성이 증가되고 ｄＧ 연속서열이결합된 포스포다이에스터 ＣｐＧ올리고데옥시뉴클레오티드 변형체
JP2005525414A5 (fr)
RU2815763C1 (ru) Композиция для иммуностимуляции и ее применение
EA051416B1 (ru) Применение искусственно синтезированного одноцепочечного cpg-дезоксиолигонуклеотида в вакцинах
WO2025113554A1 (fr) Composition vaccinale contre varicelle-zona et son utilisation
WO2002011761A2 (fr) Vaccin contre le virus respiratoire syncytial (rs)
Madaan Heplisav V
HK1143062A (en) Use of nucleic acids containing unmethylated cpg dinucleotide as an adjuvant

Legal Events

Date Code Title Description
FZDE Discontinued